Electroporation-based Transfection Demonstrates Consistent Antibody Quality and Glycosylation Patterns for Biotherapeutic Product Development

By on December 15, 2016
Consistent Antibody Quality and Glycosylation Patterns Support the Use of MaxCyte’s Electroporation-based Transfection for Biotherapeutic Product Development.

Increasingly, companies are choosing CHO-based transient production of antibodies in early biopharmaceutical development over stable cell line generation. The advantage of using transient transfection is that it takes significantly less time and cost to generate material when compared with the alternative of developing a genetically stable cell line for manufacturing. This is particularly important in drug development where preclinical material is needed quickly in order to make informed go/no go decisions. Having access to preclinical material faster and with less cost can greatly impact the overall drug development timeline.

By initially using transient production, gram quantities of material can be generated quickly and cost effectively, with the plan that if the product progresses further in development, a stable cell line will be generated for larger scale manufacturing. However, for biotherapeutic development to fully benefit from transient production, it must be demonstrated that the transiently produced candidate accurately represents the product that will ultimately be manufactured via a stable cell line. Thus characteristics, such as protein quality and the glycosylation profile must be similar between the transiently produced material and stably produced material.

Product quality and glycosylation are particularly important because post-translational modifications can greatly impact biotherapeutic efficacy and pharmacokinetics. Proteins are often glycosylated, which is a process where proteins are post-translationally modified with the addition of sugar residues. Hence, to maintain the integrity of the candidate selection process, the glycosylation pattern must remain similar between starting material and larger scale manufacturing.

As part of our Boston Biotech Week 2016 coverage, we will be writing about some of the posters presented at the conference. One poster that examined this topic in depth was “Consistent Antibody Quality and Glycosylation Patterns Support the Use of MaxCyte’s Electroporation-based Transfection for Biotherapeutic Product Development,” presented by MaxCyte. In the poster, MaxCyte presents data on protein quality and glycosylation patterns for antibodies and Fc fusion proteins produced transiently as compared to materials produced using a stable cell line. The data presented demonstrate the reproducibility of MaxCyte’s transient expression system and that transiently produced proteins mimic product qualities of stably produced proteins. In addition, long term stability of titers and protein quality in stable cell lines generated via MaxCyte electroporation were presented.

Highlights of the poster include:

CHO-based Transient Production Resulted in High Quality Proteins

The MaxCyte electroporation-based platform is flexible able to efficiently transfect a variety of CHO cell lines including CHO-S, CHO-K1, CHO EBNA, CHO-K1SV, and CHOZN®. High titers, consistent protein quality and reproducibility were demonstrated when compared with other transfection methods (Figure 1, 2)

CHOZN®: Gel Analysis of Protein Quality and Titer

50Kda Heavy Chain and the 25Kda Light Chain Are Clearly Seen

Fig 1: CHOZN®: Gel Analysis of Protein Quality and Titer

Figure 1: Titers & SDS PAGE analysis of transiently expressed IgGs. CHOZN® cells were electroporated using the MaxCyte STX – three independent runs. Conditioned media samples were collected on days 5-8 and analyzed for IgG titers. Samples from day 8 post EP were run on a Novex 4-20% SDS PAGE Tris Glycine gel and stained with Coomassie Blue G-250. Bands of the correct size for hIgG heavy and light chains are clearly evident on a reducing gel loaded with unpurified media samples and Protein A purified samples. No additional bands are evident in the purified samples, indicating good protein quality.

MX CHOK1-SV: Low Degradation Fc Production

MaxCyte Outperforms Expi293 & ExpiCHO

fig 2: MX CHOK1-SV: Low Degradation Fc Production

Figure 2: Higher Titers & Less Degradation Using MaxCyte Electroporation. CHOK1-SV cells were transfected with expression plasmids for three Fc molecules via small scale electroporation on the MaxCyte STX. Expi293 & ExpiCHO cells were transfected using their respective standard protocols. Expi293 cultures were generally not viable post d5 (data not shown). A). Media were collected at various time points post transfection and titers determined using an Octet® System. B). Day 5 supernatants for MaxCyte, Expi293 and ExpiCHO transfected cell titers are compared. C). 15ul of sample/lane were run on a reduced 4-12% BT using MES buffer. For 2 of the 3 Fc fragments, MaxCyte titers were significantly higher than both Expi systems. Lower levels of degradation were apparent for MX-produced Fc fragments.

Transient Produced Material Was Consistent with Stably Produced

MaxCyte electroporation was used to transiently produce protein and also to generate stable cell lines that expressed the same protein. Then the transiently expressed protein was compared side-by-side with the stably produced protein. from eachwere then expressed transiently or stably produced were then compared side-by-side.
 The transiently produced proteins demonstrated similar protein characteristics and glycosylation patterns to the proteins produced using the stable cell lines (Figure 3). Thus, supporting the use of transiently produced protein in early stage biotherapeutic development.

Equivalent Antibody Quality & Glycosylation

Similar IgGs Produced via MaxCyte Transient Transfection & Stable Cell Lines Generated Using MaxCyte Transfection

fig 3: Equivalent Antibody Quality & Glycosylation

Figure 3: hIgG1 Quality & Glyco-form Comparison – Transient vs Stable Expression. A human IgG molecule was expressed transiently in CHO-S cells via four independent static electroporations with the MaxCyte STX. A stable cell line (S17) was also generated by subjecting transfected cells to antibiotic selection, followed by limited dilution cloning. A). SDS-PAGE gel analysis (reducing and non-reducing) data indicate equivalent quality (i.e aggregation or degradation) of antibodies produced via transient or stable transfection. B.) Glycoform analysis showed highly consistent patterns of post-translational modification among the different transient transfection runs as well as the protein produced from media harvested from the stable cell line.

MaxCyte Electroproation Rapidly Generates High-producing Cell Lines That Maintain Titer, Quality and Glycosylation Over Time

An additional benefit of using this system was the efficient generation of stable cell lines following electroporation. Due to the high CHO cell viability post electroporation, it was possible to generate stable pools and develop stable clones with yields
>5.7 g/L in just 6 weeks. Less than 500 clones were needed for screening to identify a high-yield stable cell line. Furthermore, these stable cell lines maintained protein titers, quality and glycosylation patterns over 90 days (Figure 4).

Stability of MaxCyte-produced Cell Lines

 Stability of MaxCyte-produced Cell Lines

 

A. Top Producing Stable Cell Line 6 weeks Post EP

fig 4b: Top Producing Stable Cell Line 6 weeks Post EP

B. Titer & Glyco-form Analysis

fig 4b: Titer & Glyco-form Analysis

C. Protein Quality

Fi 4c: Protein Quality

Figure 4: Analysis of IgG Titers, Post-Translational Modifications and Protein Quality of a MaxCyte-produced Stable Cell Line Over Passage. CHO-S cells were subjected to antibiotic selection and limited dilution cloning following static electroporation with the MaxCyte STX. A stable pool was generated within 2 weeks of electroporation. 479 clones were screened following limited dilution cloning. A). The top clone (S17) was selected for production within 6 weeks post transfection. The production was carried out in shake flasks as a fed batch. At day 17 productivity reached over 5.7 g/L. B). Cell banks were generated from S17 at three different time points post selection (day 0, day 30 and day 60). Cells from the three cell banks were thawed and proteins were produced in fed batch cultures. Less than 15% loss in titer was observed after 60 days in culture, and glycoform patterns remained consistent. C). Proteins produced by the three cell banks were purified using Protein A and analyzed via SDS-PAGE analysis. No loss in protein quality was observed.

For more data and full details of the highlights discussed here, please click on the poster below to view in full size.

view MaxCyte Protein Quality PosterSave

Save

Save

Leave a Reply

Your email address will not be published. Required fields are marked *